Ph.D. and M.A., economics, Duke University; B.A., economics, Huazhong University of Science and Technology
Summary of Experience
Dr. Zhang is a health economist with expertise in health economics and outcomes research (HEOR) who has worked on a variety of projects for pharmaceutical companies. He has experience with analyses related to treatment patterns, disease burden, cost calculation, comparative effectiveness, insurance claims, electronic medical records, chart reviews, surveys, cost effectiveness, and literature reviews. Dr. Zhang’s work spans disease areas such as oncology, hematology, dermatology, rheumatology, endocrinology, neurology, and pulmonology. His research has been presented at numerous international clinical conferences and published in several peer-reviewed journals.
Advances in Therapy, 2021
Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States
Gynecologic Oncology, 2020
A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer